0 Bewertungen0% fanden dieses Dokument nützlich (0 Abstimmungen)
41 Ansichten7 Seiten
"Ripening" refers to the use o! either pharmacologic or nonpharmacologic metho"s to pro"uce a more!avorable cervi# that is so!ter an" more e!!ace"$. The goal o! prein"uction cervical ripening is to "ecrease time to "eliver( an" possi"ble lo&er the rate o! cesarean "elive"r(
"Ripening" refers to the use o! either pharmacologic or nonpharmacologic metho"s to pro"uce a more!avorable cervi# that is so!ter an" more e!!ace"$. The goal o! prein"uction cervical ripening is to "ecrease time to "eliver( an" possi"ble lo&er the rate o! cesarean "elive"r(
"Ripening" refers to the use o! either pharmacologic or nonpharmacologic metho"s to pro"uce a more!avorable cervi# that is so!ter an" more e!!ace"$. The goal o! prein"uction cervical ripening is to "ecrease time to "eliver( an" possi"ble lo&er the rate o! cesarean "elive"r(
Sarah Kilpatrick MD, PhD Basics Description Cervical maturation or cervical ripening re!ers to the use o! either pharmacologic or nonpharmacologic metho"s to pro"uce a more !avorable cervi# that is so!ter an" more e!!ace"$ %his e!!ect &ill subse'uentl( increase the likelihoo" o! a success!ul in"uction o! labor$ %he goal o! prein"uction cervical ripening is to "ecrease time to "eliver( an" possibl( lo&er the rate o! cesarean "eliver($ Pharmacologic metho"s) o Hormonal metho"s) Prostaglan"ins o *#(tocin +onpharmacologic metho"s) o Membrane stripping o Mechanical "ilators o H(groscopic "ilators o Balloon catheter ,alone, &ith traction, &ith in!usion- o .mniotom( /pi"emiolog( Bet&een 0112 an" 3224, the rate o! labor in"uction in the 5S increase" !rom 1$67 to 30$37 o! all births nation&i"e$ Pathoph(siolog( Pharmacologic metho"s) o PG/s) 32 carbon bioactive lipi" important !or cervical maturation /3) Dinoprostones ,Cervi"il, Prepi"il- /0) Misoprostol ,C(totec- o *#(tocin ,Pitocin-) Potent en"ogenous uterotonic agent M(ometrial o#(tocin receptor concentrations increase on average 02283229!ol" "uring pregnanc(, reaching a ma#imum "uring earl( labor$ +onpharmacologic metho"s) o Mechanical release o! en"ogenous prostaglan"ins !rom the membranes an" a":acent "eci"ua, &hich ma( be involve" in stimulating m(ometrial contractions an" in the onset o! labor o Ma( trigger an autonomic neural re!le# that promotes the release o! o#(tocin !rom the maternal posterior pituitar( Diagnosis Signs an" S(mptoms Histor( Patients &ho re'uire cervical ripening are those &hose management plans inclu"e an in"uction o! labor !or either maternal or !etal in"ications$ ;n"uction re!ers to the initiation o! uterine contractions be!ore the spontaneous onset o! labor !or the purpose o! "eliver($ Cervical ripening ma( be the 0st step to in"uction$ ;mportant obstetric histor() o Histor( o! prior cesarean "eliveries) Histor( o! prior classical uterine incision contrain"icate" *ther contrain"ications to in"uction o! labor inclu"e but are not limite" to) o Placenta or vasa previa o %ransverse !etal lie o .ctive genital herpes in!ection o .llergies or a"verse reactions to me"ications ,i$e$, prostaglan"ins, o#(tocin, misoprostol- .lert PG/0 use is contrain"icate" in patients &ith histor( o! prior cesarean section or ma:or uterine surger($ Ph(sical /#am Cervical e#am &ith assessment o! "ilation, e!!acement, station, consistenc(, an" cervical position Bishop score) ;! <=, then cervical ripening recommen"e" !or an increase" likelihoo" !or a success!ul in"uction o! labor$ /ach parameter can score up to > points) o Dilation in centimeters o Close", 2 points) 083 cm, 0 point >84 cm, 3 points ?6 cm, > points o /!!acement 7) 28>27, 2 points 428627, 0 point =28@27, 3 points ?A27, > points o Station) 9>, 2 points 93, 0 point 90 or 2, 3 points B0 or B3, > points o Consistenc() Cirm, 2 points Me"ium, 0 point So!t, 3 points o Cervical position) Posterior, 2 points Mi"position, 0 point .nterior, 3 points .ssess shape an" a"e'uac( o! bon( pelvis) Clinical pelvimetr( .ssess estimate" !etal &eight an" presentation b( Deopol" maneuvers$ %ests Routine labor an" "eliver( a"mission testing +S% to assess !etal &ell being .mniotic !lui" assessment i! in"icate" ;maging 5S to con!irm verte# presentation i! nee"e" %reatment General Measures Document in"ications o! in"uction o! labor$ Revie& histor( o! an( contrain"ications to labor an"Eor vaginal "eliver($ Con!irm G.$ Determine !etal position$ Con!irm !etal &ell being$ Continuous !etal monitoring is necessar( in appropriate situations$ Pregnanc(9Speci!ic ;ssues B( %rimester Doses o! pharmacologic agents changes !rom >r" trimester in"uctions to 3n" trimester in"uctions !or termination$ *#(tocin ,Pitocin- is not as e!!ective !or in"uction o! labor compare" to other options available !or 3n" trimester in"ications$ /#act "osing consi"erations are liste" in Me"ications section belo&$ Risks !or Mother Caile" in"uction +ee" !or cesarean section %ime Discom!ort P$>=1 Risks !or Cetus ;ntolerance to uterine contractions Special %herap( Complementar( an" .lternative %herapies Mechanical "ilation using an intracervical catheter can be augmente" &ith lo&9"ose ;F Pitocin$ Me"ication ,Drugs- ;! a pharmacologic metho" is pre!erre" !or cervical ripening, the !ollo&ing "rugs can be use"$ Consi"er changing in"uction metho" a!ter 34 hours i! no progress$ Prostaglan"in /3) o >r" trimester) Prepi"il) 2$6 mg in 3$69mD gel intracervical preparation '48=h Cervi"il) 02 mg in time"9release intravaginal preparation '03h PG gel) Dinoprostone in various concentrations ,386 mg- in 02 mD gel o 3n" trimester) Dinoprostone) 32 mg suppositor( '=h Prostaglan"in /0, Misoprostol ,C(totec-) o >r" trimester) 36862 Gg '4h intravaginall( at e#ternal cervical os or posterior !orni# 62 Gg P* '4h o 3n" trimester cervical ripening an" in"uction !or termination) 0228322 Gg intravaginall( '>84h 4228A22 Gg intravaginall( '=803h o %ablets come in 02283229Gg !orms *#(tocin 084 m;5Emin, lo&9"ose, continuous in!usion .lert PG/0 use is contrain"icate" in patients &ith histor( o! prior cesarean "eliveries or ma:or uterine surger($ Si"e e!!ects) %ach(s(stole ,more !re'uent &ith 62 Gg- or h(perstimulationH nausea, "iarrhea, an" !ever Surger( ;! a nonpharmacologic metho" is pre!erre", the !ollo&ing metho"s can be use"$ Keep in min" relative contrain"ications) Mucopurulent cervical "ischarge, rupture" membranes$ Membrane stripping) o Digital separation o! chorioamnionic membrane !rom the &all o! the cervi# an" lo&er uterine segment Mechanical "ilators, balloon catheters) o ;ntracervical Cole( balloon catheter place" in the cervical canal at the lo&er uterine segment, late# or nonlate# in siIes 0A83= gauge$ o %he catheter balloon is then !ille" &ith >2 mD o! sterile normal saline$ o %raction is then applie" b( taping the catheter taut onto the patientJs thigh$ o +ormal saline solution can also be in!use" through the catheter port at >2 mDEh ,/.S;H e#tra amniotic saline in"uction-$ o Can also use concomitantl( &ith o#(tocin o ;! not e#pelle" spontaneousl( a!ter 03 hours, remove an" continue &ith another metho"$ H(groscopic "ilators) o .bsorbs &ater to s&ell an" !orcibl( "ilate the cervi# o Daminaria) Desiccate" sea&ee" o Dilapan pol(acr(lonitrile o Damicel) Magnesium sul!ate in pol(vin(l alcohol o Place" into cervical canal at internal os a!ter cleansing cervi# &ith Beta"ine o Place gauIe into vagina to keep "ilators in place$ o Remove 03834 hours a!ter placement an" procee" &ith !urther ripening or in"uction$ .lert ;! late# allerg(, balloon catheter is contrain"icate"$ Collo&up Complications Potential complications o! PG/ analogues) o Complications are "ose relate" o 5terine h(perstimulation) ;ntracervical PG/3 get ,2$6 mg-) 07 ;ntravaginal PG/3 gel or vaginal insert) 67 Subse'uent CHR "eceleration Rarel(, uterine rupture Rarel(, placental abruption *#(tocin) o 5terine rupture rare o 5terine h(perstimulation o Kater into#ication &ith high concentration an" h(potonic solutions .mniotom() o 5mbilical cor" prolapse ,rare- o Chorioamnionitis o 5mbilical cor" compression o Rupture o! vasa previa Stripping the membranes) o Blee"ing !rom un"iagnose" placenta previa or lo&9l(ing placenta o .cci"ental amniotom( Mechanical "ilators) o Risk o! maternal or neonatal in!ection Patient Monitoring Mother Kith PG preparation) o Patient shoul" remain recumbent !or at least >2 minutes$ o Recor" vital signs$ o 5terine activit( is monitore" continuousl( !or >2 minutes to 3 hours a!ter a"ministration o! PG/3 gel$ o ;! no increase in uterine activit( an" CHR unchange", ma( trans!er else&here Kith Misoprostol) o 5terine activit( monitoring in hospital setting Cetus Kith PG/3 vaginal insert) o /lectronic !etal heart rate monitoring !rom placement o! vaginal PG/3 until at least 06 min a!ter removal$ Kith misoprostol) o CHR monitoring in hospital setting Bibliograph( .C*G Committee *pinion +o$ >43$ ;n"uction o! Dabor a!ter Faginal Birth a!ter Cesarean Deliver($ Kashington, DC) .C*GH 322=$ Gabbe$ *bstetrics) +ormal an" problem pregnancies, 4th e"$ +e& Lork) Churchill DivingstoneH 3223$ Miscellaneous .bbreviations M CHRNCetal heart rate M G.NGestational age M +S%N+onstress test M PGNProstaglan"in